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Open access under the ElSickle cell anemia (SCA) is a common, severe monogenetic disorder characterized by chronic hemolysis,
frequent infections, a chronic inﬂammatory state and recurrent occlusions of the microcirculation, result-
ing in painful crises, organ damage and premature death. This study evaluated associations between
serum levels of IL-18, uric acid, hemolytic markers, and inﬂammatory molecules in SCA patients. A
cross-sectional study was performed including 45 SCA patients (median age of 20.5 years) without gen-
eral symptoms and who had not undergone blood transfusions. Inclusion criteria for the steady-state SCA
patients were the absence of hospitalization and the absence of infections. Interleukin-18 and uric acid
levels were correlated closely with markers of hemolysis, endothelial dysfunction and others cytokines
levels. These ﬁndings suggest probable inﬂuences of IL-18 and uric acid in the pathophysiology of vascu-
lar occlusion in SCA. Additional studies should be performed to characterize similar prognosis markers
and possible therapeutic targets.
 2011 Elsevier Ltd. Open access under the Elsevier OA license.1. Introduction
Sickle cell anemia (SCA) is an inherited recessive autosomal dis-
order characterized by clinical heterogeneity thatmay be supported
by a harmful environment, ethnicity, social, and economic factors
and genetic markers secondary to epigenetic phenomenon. These
genetic factors include an association between SCA and the b-S-glo-
bin gene cluster haplotypes, the presence of alpha-thalassemia and
thewell-knownprognosticmarker, the fetal hemoglobin concentra-
tion [1]. Vaso-occlusive episodes (VOE) in SCA are complex pro-
cesses governed by many factors involving interactions among
sickled red blood cells (RBC), endothelial cells, leukocytes, platelets,
coagulation factors, and plasma proteins. The chronic inﬂammatory
state that is characteristic of SCA patients [2] has been associated
withhighexpression levels of adhesionmolecules and solublemedi-
ators by the vascular endothelium as a consequence of endothelial
cell damage and activation, resulting in increased expression of sur-
face molecules on endothelial cells, RBC, platelets and leukocytes
and an increase in inﬂammatory cytokines and molecules [3].e Biologia Molecular, Centro
z (FIOCRUZ), Salvador, Bahia,
lves).
sevier OA license.The interleukin-18 is a pro-inﬂammatory cytokine that in-
duces the release of TNF-alpha, IL-1, chemokines such as IL-8,
cell adhesion molecules, and the decrease nitric oxide (NO) syn-
thesis [4,5]. Previous studies have not indicated a role for IL-18
in SCA patients, but this cytokine is known to have a strong
association with inﬂammatory events [6–9]. Increases in circulat-
ing levels of IL-18 have been described during a severe sepsis
state [10], suggesting a role for this cytokine in host defense
through leukocyte activation and in potential host damage due
to tissue lesions [11,12].
The active form of IL-18 depends on the activation of the cas-
pase-1 cascade. Caspase-1 leads to the cleavage of the pro-form
of IL-18 into a functional cytokine. The activation of caspase-1 de-
pends on a cytosolic multiprotein complex called the inﬂamma-
some. Two inﬂammasomes have been described thus far: the
NALP1 and NALP3 inﬂammasomes. The NALP3 inﬂammasome is
composed of NALP3 (NACHT, LRR and pyrin domain), the adaptor
protein ASC (apoptosis-associated speck-like protein containing a
caspase-recruitment domain), and caspase-1, and the NALP1
inﬂammasome additionally contains caspase-5. The recognition
of danger signals, such as pathogen-associated molecular patterns,
ATP and uric acid leads to oligomerization of NALP3 and associa-
tion of the inﬂammasome components, inducing the proteolytic
cleavage of procaspase-1 into its active form. The caspase-1 can
then process pro-IL-18 into IL-18 [13].
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pathogenesis of SCA, and emphasized an important role of leuko-
cytes in this process. Based on the strong evidence for the impor-
tance of inﬂammatory molecules in SCA and the lack of studies
addressing the inﬂuence of IL-18 and uric acid, we have undertaken
this study. Here we explore the association of serum levels of IL-18
and uric acid, hemolytic markers and inﬂammatory molecules in a
group of Brazilian SCA patients in order to examine the role of the
inﬂammasome in the inﬂammatory environment frequently de-
scribed in this disease.
2. Materials and methods
2.1. Study subjects
We performed a cross-sectional study composed of 45 SCA pa-
tients (21menand24women;meanageof 20.50 ± 13.99 years) that
were diagnosed according to their hemoglobin proﬁle as having
hemoglobinS (HbS)homozygous state (HbSS). Patients are routinely
follow-upat theOutpatientClinic of theHematologyandHemother-
apy Foundation – (HEMOBA) in Bahia, a Northeast Brazilian state
with the highest incidence of sickle cell disease (SCD) in Brazil. All
patients were in steady-state, which was characterized by an ab-
sence of blood transfusion in a period of four month prior to blood
sampling. Inclusion criteria for steady-state SCA patientswere char-
acterized as a period of three months without any acute events, ab-
sence of general symptoms, hospitalization, or infections.
None of patients had taken antibiotics or corticosteroids prior to
blood sampling that was withdrawn during a regular clinical visit.
The medical history data of the SCA patients were search from pa-
tients’ records.
Analyses of interleukin, arginase and soluble adhesion mole-
cules were developed in a group of controls individuals, and also
in controls pattern from the fabricant.
The control group consisted of 45 individuals who attended the
clinical laboratory of the Pharmacy College of the Federal Univer-
sity of Bahia (UFBA), and these individuals were age- and sex-
matched with the SCA patients group. The control individuals
had normal hemoglobin proﬁles and lacked a history of anemia,
inﬂammatory conditions, and hematological diseases.
The study was approved by the Oswaldo Cruz Research Founda-
tion’s Human Research Board and was in accordance with Declara-
tion of Helsinki of 1975 as revised in 2000, and all subjects or
responsible ofﬁcials ﬁlled out a written informed consent form.
2.2. Hematologic analysis
Hematological analysis was performed using an electronic cell
counter (Coulter Counter T890, Brea, CA, USA). The HbS presence
was identiﬁed by the solubility test, the sickle hemoglobin test
and by the analyses of hemoglobin proﬁle by high-performance li-
quid chromatography (HPLC) (Bio-Rad Variant, CA, USA), which as-
says were run with controls samples from patients previously
diagnosed and controls from a kit of hemoglobin pattern supplied
by manufacturers, following their recommendations. The HPLC
analysis of sample with S hemoglobin is conﬁrmed by the retention
time that is 4.30–4.70 min and it is in accord to the control pattern.
Also, the HbS presence was conﬁrmed by running electrophoresis
at alkaline pH, and acid pH. The fetal hemoglobin concentration
also has been conﬁrmed by the Betke biochemical method fol-
lowed spectrophotometer measurement.
2.3. Serum measurement of soluble adhesion molecules (sICAM-1 and
sVCAM-1)
The serum soluble intercellular adhesion molecule (sICAM-1)
and soluble vascular adhesion molecule (sVCAM-1) levels of theSCA patients were measured using a human DuoSet ELISA Kit
(R&D, Minneapolis, MN, USA).
2.4. Biochemical analyses
Serum concentrations of lipid molecules, hemolytic markers,
hepatic function markers, C-reactive protein, and uric acid of all
of the patients were determined using commercially available kits
(Flexor 80, Netherlands).
2.5. Cytokines and serum arginase level measurements
Interleukin-10, IL-17 and IL-18 were measured using Cytokine
ELISA OptEIA kits (BD Pharmingen, San Diego, CA, USA; eBio-
science, San Diego, CA, USA). Arginase levels were measured using
a Human Arginase I ELISA Kit (Cell Science, Canton, MA, USA)
according to the manufacturer’s recommendations.
2.6. Statistical analysis
Baseline characteristics are summarized as means and propor-
tions of selected variables. The distribution of quantitative vari-
ables was determined using the Kolmogorov–Smirnov test. Mean
values of quantitative variables between groups were compared
using an unpaired t-test for data distributed normally and a
Mann–Whitney test for non-normal data. Bivariate correlation
analyses were carried out to determine correlations between pairs
of variables using Pearson’s and Spearman’s rank correlation (R).
All tests were considered signiﬁcant if p values were less than
0.05. Data analyses were performed using the STATA 10 (StataCorp,
Texas, USA) and GraphPad Prism 5 (Graphpad Software, San Diego,
CA) software packages.
3. Results
3.1. Medical history
The most common clinical complications in the SCA patients
were the occurrence of a painful crisis, 41/43 (98.3%); followed
by infection, 25/43 (58.1%); pneumonia, 16/43 (37.2%); leg ulcer,
8/43 (18.6%); cholelithiasis, 8/43 (18.6%); splenic sequestration,
7/43 (16.3%); priapism, 3/21 (14.3%); splenectomy, 6/43 (14.0%);
acute chest syndrome, 6/43 (14.0%); hepatomegaly, 6/43 (14.0%);
osteomyelitis, 3/43 (7.0%); dactylitis, 3/43 (7.0%); avascular necro-
sis, 2/43 (4.7%); retinopathy, 1/43 (2.3%); stroke, 1/43 (2.3%), and
aplastic crisis, 1/43 (2.3%). The laboratory proﬁle of these patients
is shown in Table 1.
3.2. Cytokines, biochemical and soluble adhesion molecule
concentration among sickle cell anemia patients and individuals from
a control group
Cytokines, arginase, uric acid, and soluble adhesion molecule
serum levels on SCA patients and individuals from a healthy group
are shown in Table 2.
3.3. IL-18 and uric acid
IL-18 was positively associated with the serum concentration of
uric acid (p = 0.042; r = 0.361) (Fig. 1).
3.4. IL-18 and hemolytic markers
IL-18 was positively associated with lactate dehydrogenase
(LDH) (p = 0.001; r = 0.547) (Fig. 2A). Nine patients had IL-18
Table 1
Baseline characteristics of the steady-state sickle cell anemia patients.
Characteristics Patients
N Mean ± SD
Age (Years) 45 20.49 ± 13.99
Gender
Male 21
Female 24 –
Hemoglobin proﬁle
S 45 86.30 ± 9.47
Fetal 45 6.85 ± 3.89
Hemolysis
RBC ( 106/mm3) 45 2.72 ± 0.68
Hemoglobin (g/dL) 45 8.09 ± 1.60
Hematocrit (%) 45 24.42 ± 5.20
Mean cell volume (fL) 45 91.06 ± 9.02
Mean cell hemoglobin (pg) 45 30.16 ± 3.69
Reticulocyte count (%) 45 7.16 ± 3.69
Erythroid precursors 45 1.27 ± 5.84
Leukocytes
WBC ( 109/L) 45 11.87 ± 3.62
Neutrophil ( 109/L) 45 5.75 ± 1.53
Lymphocyte ( 109/L) 45 4.71 ± 1.34
Monocyte ( 109/L) 45 0.55 ± 0.40
Platelets
Platelet Count ( 109/L) 45 373.24 ± 183.40
Markers of lipid metabolism and inﬂammation
Total cholesterol (mg/dL) 45 158.53 ± 43.18
HDL cholesterol (mg/dL) 45 42.93 ± 9.84
LDL cholesterol (mg/dL) 45 87.48 ± 47.39
VLDL cholesterol (mg/dL) 45 28.12 ± 16.19
Triglycerides (mg/dL) 45 140.60 ± 80.99
Uric acid (mg/dL) 45 4.40 ± 2.02
C-reactive protein (mg/L) 45 11.73 ± 25.39
Markers of hepatic dysfunction and hemolysis
Aspartate aminotransferase (U/L) 45 32.78 ± 14.84
Alanine aminotransferase (U/L) 45 7.29 ± 4.73
Total bilirubin (mg/dL) 45 1.89 ± 1.10
Direct bilirubin (mg/dL) 45 0.58 ± 0.24
Indirect bilirubin (mg/dL) 45 1.31 ± 0.95
Lactate dehydrogenase(U/L) 45 720.98 ± 257.09
RBC, Red Blood Cell; WBC, White Blood Cell; HDL-C, High-Density Lipoprotein
Cholesterol; LDL-C, Low-Density Lipoprotein Cholesterol; VLDL-C, Very Low-Den-
sity Lipoprotein Cholesterol.
Table 2
Cytokines, hemolytic marker and soluble adhesions molecule between 45 sickle cell
anemia patients and 45 individuals from a healthy group and controls patterns.
Patients Healthy group P value*
Median SD Median SD
Cytokine
IL-10 (pg/mL) 8.87 1.52 9.90 3.22 0.248
IL-17 (pg/mL) 4.58 8.86 2.52 5.14 0.011
IL-18 (pg/mL) 3142.08 1374.81 393.4a 339.3a –
Hemolytic marker
Arginase (ng/mL) 25.77 17.97 14.70 5.36 0.005
Soluble adhesion molecule
ICAM-1 (ng/mL) 411.66 102.81 237.59 66.18 0.0001
VCAM-1 (ng/mL) 756.39 383.80 263.62 75.42 0.0001
SD, Standard Deviation; ICAM-1, Intercellular Adhesion Molecule; VCAM-1, Vas-
cular Adhesion Molecule.
* Mann–Whitney test.
a Controls pattern provided by the manufacturer.
Fig. 1. IL-18 and uric acid. Serum levels of IL-18 are positively correlated with uric
acid levels. Spearman’s⁄, P < 0.05.
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tions of LDH and indirect bilirubin; eight patients had IL-18 values
less than the 25th percentile with low serum concentrations of LDH
and indirect bilirubin (Fig. 2B and 2C). The serum concentration of
IL-18 was positively associated with the percentage of erythroid
precursors (p = 0.022; r = 0.396) (Fig. 2D).3.5. Uric acid and hemolytic markers
Uric acid was positively associated with total bilirubin
(p = 0.030; r = 0.338) (Fig. 3A) and indirect bilirubin (p = 0.028;
r = 0.331) (Fig. 3B). Eleven patients had uric acid values greater
than the 75th percentile with a high serum concentration of argi-
nase and indirect bilirubin; twelve patients had uric acid values
less than the 25th percentile with low serum concentrations of
arginase and indirect bilirubin (Fig. 3C and D).
3.6. Uric acid, soluble adhesion molecules and lipids
Uric acid was positively associated with sVCAM-1 (p = 0.030;
r = 0.327) (Fig. 4A). Eleven patients had uric acid values greater
than the 75th percentile with high serum concentrations of
sVCAM-1 and low serum concentrations of low-density lipoprotein
cholesterol (LDL-C), 12 patients had uric acid values less than the
25th percentile with low serum concentrations of sVCAM-1 and
high serum concentrations of LDL-C (Fig. 4B and C).
3.7. Uric acid and cytokines
Uric acid was positively associated with the serum concentra-
tion of IL-10 (p = 0.030; r = 0.352) (Fig. 5A). Eleven patients had uric
acid values greater than the 75th percentile with high serum con-
centrations of IL-17; 12 patients had uric acid values less than the
25th percentile with low serum concentrations of IL-17 (Fig. 5B).4. Discussion
The defect in vascular homeostasis in SCA is caused by endothe-
lial activation, cell interaction, inﬂammatory molecules and the
inﬂuence of coagulation factors, resulting in vascular occlusion
and the clinical phenotype characteristic of patients [2,14]. These
clinical aspects are correlated with the expression of cytokines pro-
ﬁles, such that the disruption of the cytokine balance should pre-
cipitate the occlusive events by inducing endothelial cell
activation [15]. Our study examined the possible participation of
IL-18 and uric acid in vascular events and their association with
cytokines, hemolytic markers and lipid markers, implicating the
inﬂammasome in SCA patients.
We ﬁrst demonstrated a positive association between IL-18 and
uric acid in the group of SCA patients. This result may indicate the
participation of the inﬂammasome pathway [16] in the inﬂamma-
tory events occurring in SCA patients, with the participation of uric
acid being the ﬁnal product of cellular catabolism of purine and
monosodium urate crystals in their active form [17]. These com-
pounds have previously been indicated as danger signals that
Fig. 2. Hemolitic markers and serum levels of IL-18 in SCA patients. (A) Positive correlation between serum levels of IL-18 and LDH. (B) Increased serum levels of LDH are
associated with high serum levels of IL-18. (C) Increased serum levels of indirect bilirubin are associated with high serum levels of IL-18. (D) Positive correlation between
serum levels of IL-18 and erythroid precursors. Spearman’s⁄, P < 0.05; Test-T⁄⁄, P < 0.05; Mann–Whitney Test⁄⁄⁄, P < 0.05.
Fig. 3. Hemolitic markers and serum levels of uric acid. (A and B) Positive correlation between serum levels of bilirubins and uric acid. (C) Increased serum levels of arginase
are associated with high serum levels of uric acid. (D) Increased serum levels of indirect bilirubin are associated with high serum levels of uric acid. Spearman’s⁄, P < 0.05;
Test-T⁄⁄, P < 0.05; Mann–Whitney Test⁄⁄⁄, P < 0.05.
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Fig. 4. Soluble adhesion molecules, lipids and uric acid. (A) Positive correlation between serum levels of sVCAM-1 and uric acid. (B) Increased serum levels of sVCAM-1 are
associated with high serum levels of uric acid. (C) Decreased serum levels of LDL-C are associated with high serum levels of uric acid. Spearman’s⁄, P < 0.05; Test-T⁄⁄, P < 0.05;
Mann–Whitney Test⁄⁄⁄, P < 0.05.
Fig. 5. Cytokines and uric acid. (A) Positive correlation between serum levels of IL-10 and uric acid. (B) Increased serum levels of IL-17 are associated with high serum levels
of uric acid. Spearman’s⁄, P < 0.05; Mann–Whitney Test⁄⁄⁄, P < 0.05.
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and the production of IL-1 beta and IL-18 [18]. Therefore, this path-
way should have a role in the pro-inﬂammatory cytokines that par-
ticipate in the clinical proﬁle of SCA patients.
The IL-18 is a pleiotropic cytokine related to innate immune de-
fense [19], inducing acute inﬂammation and promoting neutrophil
accumulation [20]. These functions may also be possible inﬂuences
of IL-18 on the well-described vascular events in SCA. In this study,
we demonstrate a positive association between IL-18 and hemo-
lytic markers such as LDH. The measurement of this enzyme in
SCA patients has been characterized by Taylor et al. [21] to predict
disease survivors. High serum levels of LDH represent an increased
risk of early mortality. Thus, increased serum levels of LDH to-
gether high serum levels of a pro-inﬂammatory cytokine like IL-
18 could be considered possible risk factors, and patients present-
ing these indicators likely will have a poor prognosis; this hypoth-
esis that should be conﬁrmed by a clinical prospective study.
In addition, not only is uric acid a marker of catabolic rate, but
some authors suggest that increased serum levels of uric acid may
promote arteriolosclerosis [22], atherosclerosis [23] and organ
damage [24], perhaps by exerting a deleterious effect on endothe-
lial cell function [25]. Uric acid can act as a pro-oxidant, particu-
larly at high concentrations, and thus may be a marker of
oxidative stress; it may also have a therapeutic role as an antioxi-
dant [26]. These observations illustrate a potential negative contri-
bution for high serum concentrations of uric acid in SCA. Our
results conﬁrm this assertion as we show an association between
increased serum concentrations of uric acid and sVCAM-1 (an
endothelial activation marker) and classical markers of a chronic
hemolytic state such as bilirubin and arginase [27].
The negative inﬂuence of uric acid may be associated with the
activation of the inﬂammasome complex and other oxidativemechanisms. Ruggiero et al. [28] have observed a progressive lin-
ear increase of uric acid that is positively associated with pro-
inﬂammatory and anti-inﬂammatory cytokines. Pfeffer et al. [29]
and Terada et al. [30] have described the inﬂuence of TNF-alpha,
IL-1, IL-6 and oxygen tension on xanthine oxidoreductease (XO) gene
transcription, which lead to a simultaneous increase in uric acid
and free radical production, resulting in endothelial dysfunction
[31]. In our study, we observed a positive correlation between high
serum concentrations of uric acid and IL-10, IL-17, and IL-18 levels.
Our hypothesis is that the proﬁle of chronic hypoxia and inﬂamma-
tion presented by SCA patients results in the up-regulation of the
XO, a key metabolic enzyme in the purine pathway. These ﬁndings
also suggest that uric acid levels indirectly reﬂect a pro-inﬂamma-
tory state, hypoxia and the presence of free radicals.
Further, the participation of uric acid in oxidative metabolism
has been characterized by Patterson et al. [32], who demonstrated
that uric acid protects native low-density lipoprotein cholesterol
(LDL-C) against oxidation by transition metal ions, but accelerates
the oxidation of mildly oxidized LDL-C. This shows the strong inﬂu-
ence of uric acid on complex mechanisms related to oxidative
stress and endothelial activation. Our results demonstrate a possi-
ble association between LDL-C and uric acid, in which patients
with low concentrations of LDL-C presented increased concentra-
tions of uric acid. The low levels of LDL-C in SCA patients [33,34]
may reﬂect a down-regulation of cholesterol biosynthesis [35],
an increase plasma volume having a dilution effects on plasma
constituents [36] or a signiﬁcant increase in cholesterol utilization
during this hemolytic anemia [37]. The combination of these pos-
sibilities illustrates that low serum levels of LDL-C and increases in
the uric acid concentration may reﬂect a worse level of hemolytic
anemia, a virtual absence of atherosclerosis, and consequently a se-
vere clinical version of SCA.
476 B.A.V. Cerqueira et al. / Cytokine 56 (2011) 471–4765. Conclusion
We conclude that both the inﬂammasome and molecules such
as IL-18 and uric acid are involved in vascular occlusion in SCA
and that molecules are strongly associated with classical hemolytic
and endothelial activation markers, illustrating the important role
of this complex event in SCA.
On the basis of our results, additional studies are warranted to
determine whether these molecules have utility as easily assess-
able markers for assessing the relative risk of vascular events and
possible therapeutic targets in SCA patients.Conﬂict of interest disclosure
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